MedImmune News
Most Popular MedImmune Story
Will Big Pharma buy Biogen Idec?
So, Big Pharma--you all want to make a deal with biotech. But who's most likely to step up to the plate for Biogen Idec? Analysts put the price tag at $25 billion to $30 billion, so only the... Read more...
Latest Headlines
- December 23, 2009
- August 20, 2009
- July 31, 2009
- January 7, 2009
- July 1, 2008
- December 21, 2007
- October 24, 2007
- October 15, 2007
- September 20, 2007
- September 10, 2007
- September 6, 2007
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
